Journal of Critical Care
Volume 24, Issue 1 , Pages 43-49, March 2009

Clinical implications of new neuromuscular concepts and agents:☆

So long, neostigmine! So long, sux!

Department of Anesthesiology, Harbor-UCLA Medical Center, Torrance, CA 90509, USA

published online 19 January 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ The authors have in the past received supports for their neuromuscular researches from various sponsors including Organon, USA, Inc, now a part of Schering-Plough Corporation, owner of sugammadex. One author (CL) is coprincipal investigator and coinventor of the TAAC3 series of compounds (now deactivated) cited in the text as reference 8, which was in the past sponsored in part by said sponsor. He is also principal investigator of a multicenter study on sugammadex, cited as reference 4, which was also sponsored by the same sponsor.

PII: S0883-9441(08)00191-3

doi:10.1016/j.jcrc.2008.08.009

Journal of Critical Care
Volume 24, Issue 1 , Pages 43-49, March 2009

Article Tools